MedTrace Logo

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

NCT00953771 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-07-23

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to find out if administration of danazol with plasma exchange and corticosteroids will reduce the number of plasma exchanges required to control Thrombotic Thrombocytopenic Purpura (TTP).

Conditions

  • Thrombotic Thrombocytopenic Purpura

Interventions

DRUG

Danazol

Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.

Sponsors & Collaborators

Principal Investigators

  • Ilan Shapira, M.D. · Mount Sinai St. Luke's-Roosevelt

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2015-11-19
Completion
2015-11-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953771 on ClinicalTrials.gov